Wijdan Rai, MD
Neurology · Sioux Falls, SDNPI 1558747279
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (40.1%), grants and travel and lodging — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by TG Therapeutics, Inc. at 50.6% of the total. 2025 is the largest year on record at $48,956, 2.4 times the $20,088 reported in 2020. Among neurology clinicians in SD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 173 payments — averaging $470.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- TG Therapeutics, Inc.$41K
- Medtronic$23K
- EMD Serono, Inc.$9K
- Amgen$3K
- Boston Scientific$2K
- Abbott$1K
- plus $2K from 18 others
What the payments were for
- Consulting fees$8,40010%
- Speaking & faculty fees$32,65040%
- Grants$20,00025%
- Travel & lodging$14,68518%
- Food & beverage$5,6337%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| TG Therapeutics, Inc. | 45 | $41,209 |
| Medtronic(2 entities) | 28 | $22,980 |
| EMD Serono, Inc. | 13 | $9,023 |
| Amgen(2 entities) | 12 | $2,548 |
| Boston Scientific | 17 | $2,474 |
| Abbott | 11 | $1,390 |
| Biogen | 5 | $321 |
| AbbVie | 9 | $304 |
| AstraZeneca | 3 | $229 |
| Sanofi | 3 | $153 |
| Neurocrine Biosciences, Inc. | 2 | $130 |
| Johnson & Johnson(2 entities) | 2 | $120 |
| Bristol Myers Squibb | 6 | $94 |
| Genentech USA, Inc. | 3 | $79 |
| Eisai Inc. | 1 | $67 |
| Amneal Pharmaceuticals LLC | 3 | $57 |
| Vanda Pharmaceuticals Inc. | 2 | $55 |
| Teva Pharmaceuticals USA, Inc. | 2 | $29 |
| GE HealthCare | 1 | $26 |
| Avion Pharmaceuticals | 1 | $21 |
| Acadia Pharmaceuticals Inc | 1 | $18 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| Novartis | 1 | $13 |
| Sunovion Pharmaceuticals Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BRIUMVI$40,604
- ACTIVA$20,000
- Mavenclad$8,400
- UPLIZNA$2,324
- PERCEPT PC BRAINSENSE$2,142
- VERCISE$2,102
- Infinity DBS Pulse Generators$598
- Proclaim IPG$446
- ACTIVA PC$233
- INFINITY$223
- QULIPTA$125
- INGREZZA$115
- Ponvory$104
How this compares
$81,368 in reported general payments places this provider in the 95th percentile of 49 neurology providers in South Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 34 | $395,082 |
| CopaxoneGlatiramer Acetate | 26 | $175,883 |
| Aimovig AutoinjectorErenumab-Aooe | 34 | $34,437 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 639 | $30,382 |
| QuliptaAtogepant | 24 | $29,041 |
| RytaryCarbidopa/Levodopa | 15 | $25,220 |
| Glatiramer Acetate | 12 | $23,290 |
| NeuproRotigotine | 16 | $18,107 |
| Entacapone | 97 | $14,693 |
| UbrelvyUbrogepant | 12 | $14,457 |
| Modafinil | 11 | $11,198 |
| Dalfampridine ErDalfampridine | 34 | $8,075 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 94 | $6,673 |
| Gabapentin | 202 | $3,413 |
| AmantadineAmantadine Hcl | 85 | $3,118 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Copaxone | $29 | $175,88326 claims |
| AbbVieQulipta, Ubrelvy | $304 | $43,49836 claims |
| Amneal Pharmaceuticals LLCRytary | $57 | $25,22015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 49 neurology providers in South Dakota.
Other neurology in Sioux Falls
- Andrew RidderSioux Falls$97K
- Jeffrey BoyleSioux Falls$14K
- Mehwish FarooqiSioux Falls$12K
- Bassel SalemSioux Falls$7K
- Cynthia Zevallos MauSioux Falls$6K
- Karan TopiwalaSioux Falls$4K
- Jorge SanchezSioux Falls$3K
- Nessim AminSioux Falls$1K
- Lisa ViolaSioux Falls$1K
- Xi WangSioux Falls$982
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.